Suven Life Sciences completes patient enrollment for Phase 2 POC study of SUVN-502

25 Oct 2018 Evaluate

Suven Life Sciences has completed enrollment of patients with Last-Patient-In Goal for its Phase 2 POC study of SUVN-502 for moderate Alzheimer’s disease. The company expects to report the top-line data of this study by July/August 2019 time frame.

This randomized, double-blind, placebo-controlled study is evaluating the efficacy and safety of two doses of SUVN-502 in moderate Alzheimer’s Disease patients who are taking both Aricept (donepezil) and Namenda (memantine). Study duration is 30 weeks. This is the first ever study to evaluate a triple combination therapy for moderate Alzheimer’s disease patients.

There is an urgent need for treatment options for patients with Alzheimer’s disease (AD) dementia since there are no new drugs discovered or developed from 2003 till now.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.

Suven Life Sciences Share Price

167.45 4.40 (2.70%)
30-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.60
Dr. Reddys Lab 1265.95
Cipla 1491.40
Zydus Lifesciences 901.30
Lupin 2081.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×